Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

The mGluR theory of fragile X mental retardation

Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580

Absence of expression of the FMR-1 gene in fragile X syndrome

Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476

Varieties of Repetitive Behavior in Autism: Comparisons to Mental Retardation

Bodfish, J. W., Symons, F. J., Parker, D. E., & Lewis, M. H. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005596502855 · Cited by 1,223

Correction of Fragile X Syndrome in Mice

Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979

DNA methylation represses FMR-1 transcription in fragile X syndrome

Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680

The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses

Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676

Advances in the Treatment of Fragile X Syndrome

Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521

Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome

McBride, S. M. J., Choi, C. H., Wang, Y., Liebelt, D. A., Braunstein, E. M., Ferreiro, D., Sehgal, A., Siwicki, K. K., Dockendorff, T. C., Nguyen, H. T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.038 · Cited by 484

Individual differences in reward responding explain placebo-induced expectations and effects

Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.028 · Cited by 466

From FMRP Function to Potential Therapies for Fragile X Syndrome

Sethna, F., Moon, C., & Wang, H. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1229-3 · Cited by 49

mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders

Oberman, L. M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.729819 · Cited by 46

Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer’s disease biomarkers

Gordon, B. A., Zacks, J. M., Blazey, T., Benzinger, T. L. S., Morris, J. C., Fagan, A. M., Holtzman, D. M., & Balota, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.01.019 · Cited by 49

Simulator training for maritime complex tasks: an experimental study

Hjelmervik, K., Nazir, S., & Myhrvold, A. (2018) · WMU Journal of Maritime Affairs · doi:10.1007/s13437-017-0133-0 · Cited by 47

Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials

Scahill, L. D., Hallett, V., Aman, M. G., McDougle, C. J., Arnold, L. E., McCracken, J. T., Tierney, E., Deng, Y., Dziura, J. D., & Vitiello, B. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1689-3 · Cited by 49

Multiple drug treatments that increase cAMP signaling restore long-term memory and aberrant signaling in fragile X syndrome models

Choi, C. H., Schoenfeld, B. P., Bell, A. J., Hinchey, J., Rosenfelt, C., Gertner, M. J., Campbell, S. R., Emerson, D., Hinchey, P., Kollaros, M., et al. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00136 · Cited by 46

The FRAXopathies: Definition, overview, and update

Pirozzi, F., Tabolacci, E., & Neri, G. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34113 · Cited by 48

Kinases inhibitors in lung cancer: From benchside to bedside

Singh, P. K., Singh, H., & Silakari, O. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.07.002 · Cited by 47

Dendritic protein synthesis in the normal and diseased brain

Swanger, S. A., & Bassell, G. J. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.003 · Cited by 51

Research paradigms and useful inventions in medicine: Patents and licensing by teams of clinical and basic scientists in Academic Medical Centers

Ali, A. H., & Gittelman, M. (2016) · Research Policy · doi:10.1016/j.respol.2016.03.015 · Cited by 52

A Novel Methylation PCR that Offers Standardized Determination of FMR1 Methylation and CGG Repeat Length without Southern Blot Analysis

Grasso, M., Boon, E. M. J., Filipovic-Sadic, S., van Bunderen, P. A., Gennaro, E., Cao, R., Latham, G. J., Hadd, A. G., & Coviello, D. A. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.09.004 · Cited by 45

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Hagerman, R. J., Jacquemont, S., Berry‐Kravis, E., Portes, V. D., Stanfield, A. C., Koumaras, B., Rosenkranz, G., Murgia, A., Wolf, C., Apostol, G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34978-4 · Cited by 46

Chaperone Mediated Autophagy Substrates and Components in Cancer

Ríos, J., Sequeida, Á., Albornoz, A., & Budini, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.614677 · Cited by 45

Specifying the non-specific factors underlying opioid analgesia: expectancy, attention, and affect

Atlas, L. Y., Wielgosz, J., Whittington, R. A., & Wager, T. D. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3296-1 · Cited by 44

Targeted treatments in autism and fragile X syndrome

Gürkan, C. K., & Hagerman, R. J. (2012) · Research in Autism · doi:10.1016/j.rasd.2012.05.007 · Cited by 45

Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders

Gipson, T., & Johnston, M. V. (2012) · Neural Plasticity · doi:10.1155/2012/486402 · Cited by 44

Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles

Rook, J. M., Tantawy, M. N., Ansari, M. S., Felts, A. S., Stauffer, S. R., Emmitte, K. A., KESSLER, R. M., Niswender, C. M., Daniels, J. S., Jones, C. K., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.245 · Cited by 44

Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantinePreprint

Scott-McKean, J. J., & Costa, A. C. S. (2011) · Learning & Memory · doi:10.1101/lm.024182.111 · Cited by 47

Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis

Curie, A., Yang, K., Kirsch, I., Gollub, R. L., des Portes, V., Kaptchuk, T. J., & Jensen, K. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133316 · Cited by 43

Emerging pharmacologic treatment options for fragile X syndrome

Erickson, C. A., Schaefer, T. L., & Davenport, M. H. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s35673 · Cited by 44

On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome

Costa, A. C. S. (2011) · Developmental Neuroscience · doi:10.1159/000330861 · Cited by 44

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

Forero, A., Bartlett, N. L., Beaven, A., Myint, H., Nasta, S. D., Northfelt, D., Whiting, N. C., Drachman, J. G., LoBuglio, A. F., & Moskowitz, C. H. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.710328 · Cited by 43

Development of a translational model to screen medications for cocaine use disorder II: Choice between intravenous cocaine and money in humans

Lile, J. A., Stoops, W. W., Rush, C. R., Negus, S. S., Glaser, P. E. A., Hatton, K. W., & Hays, L. R. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.05.022 · Cited by 43

Innovation in healthcare. The challenge for laboratory medicine

Price, C. P., & John, A. S. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.09.043 · Cited by 43

Effects of the antioxidants Trolox, Tiron and Tempol on neutrophil extracellular trap formation

Vorobjeva, N. V., & Pinegin, B. V. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.09.005 · Cited by 42

Researching Students with Disabilities: The Importance of Critical Perspectives

Vaccaro, A., Kimball, E. W., Wells, R. S., & Ostiguy, B. J. (2015) · New Directions for Institutional Research · doi:10.1002/ir.20084 · Cited by 39

The benefit of heart rate variability biofeedback and relaxation training in reducing trait anxiety

Lee, J., Kim, J. K., & Wachholtz, A. (2015) · Korean Journal of Health Psychology · doi:10.17315/kjhp.2015.20.2.002 · Cited by 42

Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism

Silverman, J. L., Babineau, B. A., Oliver, C. F., Karras, M. N., & Crawley, J. N. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.042 · Cited by 46

Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects

Gould, R. W., Amato, R. J., Bubser, M., Joffe, M. E., Nedelcovych, M. T., Thompson, A. D., Nickols, H. H., Yuh, J. P., Zhan, X., Felts, A. S., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.265 · Cited by 41

From De Novo Mutations to Personalized Therapeutic Interventions in Autism

Brandler, W. M., & Sebat, J. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-091113-024550 · Cited by 43

Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens

Rawat, R. R., Ruderman, D., Macklin, P., Rimm, D. L., & Agus, D. B. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0084-4 · Cited by 41

Pharmaceuticals in the Environment

Daughton, C. G. (2013) · Comprehensive analytical chemistry · doi:10.1016/b978-0-444-62657-8.00002-1 · Cited by 46

Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers

Yang, Y., Cai, J., Yin, J., Zhang, J., Wang, K.-L., & Zhang, Z. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2015.09.023 · Cited by 40

mGluR5 Ablation in Cortical Glutamatergic Neurons Increases Novelty-Induced Locomotion

Jew, C. P., Wu, C., Sun, H., Zhu, J., Huang, J.-Y., Yu, D., Justice, N. J., & Lu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070415 · Cited by 42

Subcutaneously engineered autologous extracellular matrix scaffolds with aligned microchannels for enhanced tendon regeneration

Li, W., Midgley, A. C., Bai, Y., Zhu, M., Chang, H., Zhu, W., Wang, L., Wang, Y., Wang, H., & Kong, D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119488 · Cited by 40

Chronic Pain and Addiction: Challenging Co-occurring Disorders

Pohl, M., & Smith, L. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.684621 · Cited by 40

Using genetic findings in autism for the development of new pharmaceutical compounds

Vorstman, J. A. S., Spooren, W. P. J. M., Persico, A. M., Collier, D. A., Aigner, S., Jagasia, R., Glennon, J. C., & Buitelaar, J. K. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3334-z · Cited by 43

Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors

Sensi, M., Berto, M., Gentile, S., Pinti, M., Conti, A., Pellacani, G., Salvarani, C., Cossarizza, A., Bortolotti, C. A., & Biscarini, F. (2020) · Chemical Communications · doi:10.1039/d0cc03399e · Cited by 39

Promises and challenges in pharmacoepigenetics

Smith, D. A., Sadler, M. C., & Altman, R. B. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.6 · Cited by 41

Re-evaluating the induction of bone formation in primates

Ripamonti, U., Duarte, R. A. B., & Ferretti, C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.07.053 · Cited by 38

Addressing the Genetics of Human Mental Health Disorders in Model Organisms

McCammon, J. M., & Sive, H. L. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-050048 · Cited by 42

Precision medicine informatics

Frey, L. J., Bernstam, E. V., & Denny, J. C. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw053 · Cited by 40

Review of targeted treatments in fragile X syndrome

Ligsay, A., & Hagerman, R. J. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01045 · Cited by 38

In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin

Wang, H., Osseiran, S., Igras, V., Nichols, A. J., Roider, E., Pruessner, J., Tsao, H., Fisher, D. E., & Evans, C. L. (2016) · Scientific Reports · doi:10.1038/srep37986 · Cited by 39

Fabrication and characterization of electrospun polycaprolactone and gelatin composite cuffs for tissue engineered blood vessels

Strobel, H. A., Calamari, E. L., Beliveau, A., Jain, A., & Rolle, M. W. (2017) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33871 · Cited by 38

Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson–Gilford progeria syndrome fibroblasts

Bikkul, M. U., Clements, C. S., Godwin, L. S., Goldberg, M. W., Kill, I. R., & Bridger, J. M. (2018) · Biogerontology · doi:10.1007/s10522-018-9758-4 · Cited by 38

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study

Šumová, B., Cerezo, L. A., Szczuková, L., Nekvindová, L., Uher, M., Hulejová, H., Moravcová, R., Grigorian, M., Pavelká, K., Vencovský, J., et al. (2018) · Rheumatology International · doi:10.1007/s00296-018-4190-2 · Cited by 38

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

Lapointe, S., Mason, W. P., MacNeil, M. V., Harlos, C. H., Tsang, R. Y., Sederias, J., Luchman, H. A., Weiss, S., Rossiter, J. P., Tu, D., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00875-4 · Cited by 38

Lithium: A Promising Treatment for Fragile X Syndrome

Liu, Z., & Smith, C. B. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500077p · Cited by 39

Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome

Tabolacci, E., Palumbo, F., Nobile, V., & Neri, G. (2016) · Genes · doi:10.3390/genes7080049 · Cited by 36

Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?

Budgett, R. F., Bakker, G., Sergeev, E., Bennett, K. A., & Bradley, S. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893422 · Cited by 38

Emerging biomarkers of prostate cancer (Review)

Martin, S. K., Vaughan, T. B., Atkinson, T. H., Zhu, H., & Kyprianou, N. (2012) · Oncology Reports · doi:10.3892/or.2012.1832 · Cited by 36

Taking advantage of emergence for complex innovation eco-systems

Dougherty, D. J. (2017) · Journal of Open Innovation Technology Market and Complexity · doi:10.1186/s40852-017-0067-y · Cited by 40

Fragile X syndrome: lifespan developmental implications for those without as well as with intellectual disability

Turk, J. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328349bb77 · Cited by 35

Adolescent nicotine exposure fails to impact cocaine reward, aversion and self-administration in adult male rats

Pomfrey, R. L., Bostwick, T. A., Wetzell, B., & Riley, A. L. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.08.004 · Cited by 34

2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice

Gandhi, R. M., Kogan, C. S., & Messier, C. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00070 · Cited by 36

Epigenetics, fragile X syndrome and transcriptional therapy

Tabolacci, E., & Chiurazzi, P. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36264 · Cited by 35

Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms

Singh, R. S., Turner, R. C., Nguyen, L., Motwani, K., Swatek, M., & Lucke-Wold, B. P. (2016) · Behavioural Neurology · doi:10.1155/2016/8781725 · Cited by 41

A Summary of the Biological Processes, Disease-Associated Changes, and Clinical Applications of DNA Methylation

Andersen, G. B., & Tost, J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7481-8_1 · Cited by 36

Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features

Baker, E. K., Arpone, M., Aliaga, S., Bretherton, L., Kraan, C. M., Bui, M., Slater, H. R., Ling, L., Francis, D. I., Hunter, M. F., et al. (2019) · Molecular Autism · doi:10.1186/s13229-019-0271-7 · Cited by 36

EEG as a translational biomarker and outcome measure in fragile X syndrome

Kenny, A., Wright, D., & Stanfield, A. C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01796-2 · Cited by 36

Microwave determination of sp2 carbon fraction in nanodiamond powders

Cuenca, J. A., Thomas, E. L. H., Mandal, S., Williams, O. A., & Porch, A. (2014) · Carbon · doi:10.1016/j.carbon.2014.09.046 · Cited by 35

Electrostatically mediated adsorption by nanodiamond and nanocarbon particles

Gibson, N. M., Luo, T. M., Shenderova, O. A., Koscheev, A. P., & Brenner, D. W. (2012) · Journal of Nanoparticle Research · doi:10.1007/s11051-011-0700-9 · Cited by 35

Molecular Biomarkers in Fragile X Syndrome

Zafarullah, M., & Tassone, F. (2019) · Brain Sciences · doi:10.3390/brainsci9050096 · Cited by 36

The neurochemical basis for the treatment of autism spectrum disorders and Fragile X syndrome

Hampson, D. R., Adusei, D. C., & Pacey, L. K. K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.005 · Cited by 34

In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration

Ricci, F., Catozzi, C., Ravanetti, F., Murgia, X., D’Alò, F., Macchidani, N., Sgarbi, E., Lallo, V. D., Saccani, F., Pertile, M., et al. (2017) · Pediatric Research · doi:10.1038/pr.2017.171 · Cited by 34

The multifaceted functional role of DNA methylation in immune-mediated rheumatic diseases

Vecellio, M. L., Wu, H., Lu, Q., & Selmi, C. F. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05255-5 · Cited by 34

UV-cleavable unimolecular micelles: synthesis and characterization toward photocontrolled drug release carriers

Liu, X., Tian, Z., Chen, C., & Allcock, H. R. (2012) · Polymer Chemistry · doi:10.1039/c2py20825c · Cited by 34

Drug discovery in paediatric oncology: roadblocks to progress

Adamson, P. C., Houghton, P. J., Perilongo, G., & Pritchard‐Jones, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.149 · Cited by 37

Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety

Felts, A. S., Rodriguez, A. L., Morrison, R. D., Venable, D. F., Manka, J. T., Bates, B. S., Blobaum, A. L., Byers, F. W., Daniels, J. S., Niswender, C. M., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.09.001 · Cited by 33

CD4-Positive T-Cell Recruitment in Primary-Provoked Localized Vulvodynia

Leclair, C. M., Leeborg, N. J., Jacobson‐Dunlop, E., Goetsch, M. F., & Morgan, T. K. (2014) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e3182a55591 · Cited by 33

Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective

Lee, A. W., Ventola, P. E., Budimirovic, D. B., Berry‐Kravis, E., & Visootsak, J. (2018) · Brain Sciences · doi:10.3390/brainsci8120214 · Cited by 34

Block copolymers in Alzheimer's disease therapy: A perceptive to revolutionize biomaterials

Revdekar, A., & Shende, P. K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.007 · Cited by 34

Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.

Chapleau, C. A., Lane, J. B., Pozzo‐Miller, L. D., & Percy, A. K. (2013) · Current Clinical Pharmacology · doi:10.2174/15748847113086660069 · Cited by 35

Fragile X syndrome neurobiology translates into rational therapy

Braat, S., & Kooy, R. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.01.013 · Cited by 35

Combination of pulse methylprednisolone infusions with cyclosporine‐based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation

Shishido, S., Satou, H., Muramatsu, M., Hamasaki, Y., Ishikura, K., Hataya, H., Honda, M., 浅沼, 宏., & Aikawa, A. (2013) · Clinical Transplantation · doi:10.1111/ctr.12079 · Cited by 32

Fragile X Syndrome: Psychiatric Manifestations, Assessment and Emerging Therapies

Wadell, P. M., Hagerman, R. J., & Hessl, D. R. (2013) · Current Psychiatry Reviews · doi:10.2174/157340013805289644 · Cited by 35

The Challenge of Imitating Nature

Nerem, R. M., & Schutte, S. C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00002-1 · Cited by 32

Pharmacotherapy for Fragile X Syndrome: Progress to Date

Davenport, M. H., Schaefer, T. L., Friedmann, K., Fitzpatrick, S. E., & Erickson, C. A. (2016) · Drugs · doi:10.1007/s40265-016-0542-y · Cited by 33

Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering

Strobel, H. A., Qendro, E. I., Alsberg, E., & Rolle, M. W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01329 · Cited by 33

Caregiver opinions about fragile X population screening

Bailey, D. B., Bishop, E. E., Raspa, M., & Skinner, D. (2012) · Genetics in Medicine · doi:10.1038/gim.0b013e31822ebaa6 · Cited by 31

Redox regulation of metabolic and signaling pathways by thioredoxin and glutaredoxin in NOS-3 overexpressing hepatoblastoma cells

González, R., López-Grueso, M. J., Muntané, J., Bárcena, J. A., & Padilla, C. A. (2015) · Redox Biology · doi:10.1016/j.redox.2015.07.007 · Cited by 31

A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease

Peters, K. R., Beattie, B. L., Feldman, H., & Illes, J. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.12.001 · Cited by 31

Maternal attitudes to newborn screening for fragile X syndrome

Christie, L., Wotton, T., Bennetts, B., Wiley, V. C., Wilcken, B. M., Rogers, C., Boyle, J., Turner, C., Hansen, J. P. B., Hunter, M. F., et al. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35752 · Cited by 30

Multidimensional separation of tryptic peptides from human serum proteins using reversed‐phase, strong cation exchange, weak anion exchange, and fused‐core fluorinated stationary phases

Boichenko, A. P., Govorukhina, N. I., van der Zee, A. G. J., & Bischoff, R. (2013) · Journal of Separation Science · doi:10.1002/jssc.201300750 · Cited by 30

Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis

Jagessar, S. A., Gran, B., Heijmans, N., Bauer, J., Laman, J. D., Hart, B. A. ‘., & Constantinescu, C. S. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9320-5 · Cited by 30

Enhancement of the Targeting Capabilities of the Paclitaxel-Loaded Pluronic Nanoparticles with a Glycol Chitosan/Heparin Composite

Yuk, S. H., Oh, K. S., Cho, S. H., Kim, S. Y., Oh, S., Lee, J. H., Kim, K., & Kwon, I. C. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200278s · Cited by 30

Test–retest reliability of evoked heat stimulation BOLD fMRI

Upadhyay, J., Lemme, J. D., Anderson, J., Bleakman, D., Large, T. H., Evelhoch, J. L., Hargreaves, R. J., Borsook, D., & Becerra, L. R. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.06.001 · Cited by 29

Glutamate Delta-1 Receptor Regulates Metabotropic Glutamate Receptor 5 Signaling in the Hippocampus

Suryavanshi, P. S., Gupta, S. C., Yadav, R., Kesherwani, V., Liu, J., & Dravid, S. M. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104786 · Cited by 33

Adenosine A2A receptor inhibition reduces synaptic and cognitive hippocampal alterations in Fmr1 KO mice

Ferrante, A., Boussadia, Z., Borreca, A., Mallozzi, C., Pedini, G., Pacini, L., Pèzzola, A., Armida, M., Vincenzi, F., Varani, K., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01238-5 · Cited by 26

Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date

Fung, L. K., & Hardan, A. Y. (2015) · CNS Drugs · doi:10.1007/s40263-015-0252-0 · Cited by 28

In Silico Optimization of Atrial Fibrillation-Selective Sodium Channel Blocker Pharmacodynamics

Aguilar, M., Vigmond, E. J., Nattel, S., & Comtois, P. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.01.032 · Cited by 28

Technology innovation for infectious diseases in the developing world

So, A. D., & Ruiz‐Esparza, Q. (2012) · Infectious Diseases of Poverty · doi:10.1186/2049-9957-1-2 · Cited by 29

Current and Emerging Technology Approaches in Genomics

Conley, Y. P., Biesecker, L. G., Gonsalves, S. G., Merkle, C. J., Kirk, M., & Aouizerat, B. E. (2013) · Journal of Nursing Scholarship · doi:10.1111/jnu.12001 · Cited by 28

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Gomez‐Mancilla, B., Berry‐Kravis, E., Hagerman, R. J., von Raison, F., Apostol, G., Ufer, M., Gasparini, F., & Jacquemont, S. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.857400 · Cited by 30

The Role of Glutamate in Language and Language Disorders - Evidence from ERP and Pharmacologic Studies

Li, W., Marta Kutas, A., Gray, J. A., Hagerman, R. J., & Olichney, J. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.023 · Cited by 27

Towards the convergent therapeutic potential of G protein‐coupled receptors in autism spectrum disorders

Annamneedi, A., Gora, C., Dudas, A., Leray, X., Bozon, V., Crépieux, P., & Pellissier, L. P. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16216 · Cited by 29

Conceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndrome

Fung, L. K., Quintin, E., Haas, B. W., & Reiss, A. L. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328351823c · Cited by 27

BmK CT-conjugated fluorescence nanodiamond as potential glioma-targeted imaging and drug

Fu, Y., An, N., Zheng, S., Liang, A., & Li, Y. (2011) · Diamond and Related Materials · doi:10.1016/j.diamond.2011.10.010 · Cited by 28

Alda‐1 modulates the kinetic properties of mitochondrial aldehyde dehydrogenase ( ALDH 2)

Belmont-Díaz, J., Yoval‐Sánchez, B., Calleja, L. F., Vázquez, J. P. P., & Rodríguez‐Zavala, J. S. (2016) · FEBS Journal · doi:10.1111/febs.13833 · Cited by 30

Epigenetic modification of the FMR1 gene in fragile X patients leads to a differential response to the mGluR5 antagonist AFQ056

Jacquemont, S., Curie, A., Portes, V. D., Torrioli, M. G., Berry‐Kravis, E., Hageman, R., Ramos, F. J., Cornish, K. M., He, Y., & neri, G. (2011) · Cited by 2

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

Tabolacci, E., Pirozzi, F., Gomez‐Mancilla, B., Gasparini, F., & Neri, G. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-13 · Cited by 15

Progress toward therapeutic potential for AFQ056 in Fragile X syndrome

Doering, L. C., Sourial, M. M., & Cheng, C. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s27044 · Cited by 8

mGlu5 as a potential therapeutic target for the treatment of fragile X syndrome

Robertson, L. (2013) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzt001 · Cited by 1

Fragile X syndrome therapy: to respond or not to respond may be a matter of methylation

Pouladi, M. A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01663.x · Cited by 1